973.726.4858
973.615.3900
  
  Realistic Assessments • Experienced Insights • Practical Recommendations    
 
 
Home (What we do) How we work Case studies Get to know us Investment evaluations Let’s get started
 
 
     
A client’s leading potential aquisition was being auctioned by a merchant bank, R&S’s analysis showed over-inflated value and potential unreported conflicts in the data presented. Their client passed, and so did the competition. For more details, call 973.726.4858.
A 2nd generation medical device was ready but the 1st generation was still unaccepted in the market, so the principals identified a new use, opening the flood gates. Find out more by calling 973.726.4858.
A large medical device company wanted projections for a new surgical technology. Despite huge hype, R&S’s projected growth curve and analysis suggested a “wait policy” which competitors now wish they had followed. Don’t wait, call now for the whole story 973.726.4858.
A team approach developed a study that unveiled a $1 billion opportunity in the cosmetic procedure market, giving a technology licensing company the confidence to form a new commercialized subsidiary. Learn what was unique about this study: call 973.726.4858.
An R&S segmentation study identified market potential, competitive assessment, and critical mass of the most advantageous entry strategy for a Fortune 100 medical company. Learn how the various entry strategies were significantly different: call 973.726.4858.
Thought leader interviews pointed the way towards a clinical study and the price recommendations proposed by our principals so that payers would accept the fees for a new physician service. Payer, Provider, or Patient—who is the driver in today’s market for your product: call 973.726.4858.
Not every great product is economically viable, but an R&S study, development plan, and analysis cleared the way for a new anti-inflammatory compound. Figure out what made a difference by calling 973.726.4858.
From a list of 100s, six potential synergistic acquisition candidates were identified for a Fortune 100 medical device company. Call 973.726.4858 for the whole scoop on how this was possible.
R&S insights cut through perceptually conflicting information to identify current technology that not only pre-empted proposed applications of industry “thought leaders,” but prevented their client from making a multi-million dollar mistake based on inaccurate conclusions. Ask better questions, get better answers: call 973.726.4858 for all the details.
Want examples of our impact?
Accurate acquisition valuation
Maximizing pipeline
management
When to pull the plug
Commercialize vs. out-license technology
Ultimate market entry strategy
Maximize payer reimbursement
Evaluating financial viability
Identifying realistic acquisition targets
Turn “data” into insightful information
 
  Learn more…
right arrow Contact us and let’s get started
right arrow Case studies provide examples of our impact
right arrow How we maximize investor value
 

More on Bob and Steve

Bob Lieberman: For over 20 years, Bob has stretched the capabilities of companies to envision “what could be” for their products, customers and employees. As a principal at BDF (following success at Lever Brothers and Branch Industries), Bob led new product introductions, channel development and market viability studies throughout the biotech, diagnostic, device and pharmaceutical industries.

His drive to assess key opportunities in any situation has led clients to admire his ability to “reach the skies” while keeping his feet on the ground with a practical, sound approach to address each company’s individual challenges and problems.

With a BA in political science from SUNY and an MBA from Pace University, Bob has always found a way to combine the theoretical with the practical in a no-limits approach to opportunities for his clients.

 

Steve Pincus: Steve is the process challenger: engaging the key players, asking key questions that challenge convention, and identifying how the make the impossible happen and the improbable practical.

For 20 years, he has led paradigm-shattering initiatives at Unilever, Amstar, GE and BDF. During his career, he has patented a number of process improvement systems, which have impacted change enhancements on the domestic and international fronts.

Steve’s ability to leverage current capabilities with potential opportunity has made Roberts & Stephens a partner with various companies focusing on capital investing.

Steve earned his BS degree in Chemical Engineering from The Cooper Union followed by his MS at the City College of New York. Enough said.

 
     
 
 
© Roberts & Stephens LLC. All rights reserved.
45 Park Place South, #238
Morristown, NJ 07960
973.726.4858
 |